ROCKET LAB USA INC (RKLB)

US7731221062 - Common Stock

24.87  +1.65 (+7.11%)

After market: 25.2 +0.33 (+1.33%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to RKLB. RKLB was compared to 64 industry peers in the Aerospace & Defense industry. The financial health of RKLB is average, but there are quite some concerns on its profitability. RKLB is valued quite expensive, but it does show an excellent growth.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

RKLB had negative earnings in the past year.
RKLB had a negative operating cash flow in the past year.
In the past 5 years RKLB always reported negative net income.
In the past 5 years RKLB always reported negative operating cash flow.

1.2 Ratios

The Return On Assets of RKLB (-16.33%) is worse than 72.31% of its industry peers.
RKLB has a Return On Equity of -44.86%. This is in the lower half of the industry: RKLB underperforms 67.69% of its industry peers.
Industry RankSector Rank
ROA -16.33%
ROE -44.86%
ROIC N/A
ROA(3y)-15.03%
ROA(5y)-17.99%
ROE(3y)-23.3%
ROE(5y)-28.61%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

With a Gross Margin value of 26.06%, RKLB perfoms like the industry average, outperforming 60.00% of the companies in the same industry.
RKLB does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 26.06%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

5

2. Health

2.1 Basic Checks

RKLB does not have a ROIC to compare to the WACC, probably because it is not profitable.
RKLB has more shares outstanding than it did 1 year ago.
Compared to 1 year ago, RKLB has a worse debt to assets ratio.

2.2 Solvency

An Altman-Z score of 9.47 indicates that RKLB is not in any danger for bankruptcy at the moment.
RKLB has a better Altman-Z score (9.47) than 92.31% of its industry peers.
RKLB has a Debt/Equity ratio of 0.97. This is a neutral value indicating RKLB is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.97, RKLB is not doing good in the industry: 75.38% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.97
Debt/FCF N/A
Altman-Z 9.47
ROIC/WACCN/A
WACC9.72%

2.3 Liquidity

A Current Ratio of 2.58 indicates that RKLB has no problem at all paying its short term obligations.
With a decent Current ratio value of 2.58, RKLB is doing good in the industry, outperforming 63.08% of the companies in the same industry.
RKLB has a Quick Ratio of 2.16. This indicates that RKLB is financially healthy and has no problem in meeting its short term obligations.
RKLB's Quick ratio of 2.16 is fine compared to the rest of the industry. RKLB outperforms 76.92% of its industry peers.
Industry RankSector Rank
Current Ratio 2.58
Quick Ratio 2.16

More info and screens

7

3. Growth

3.1 Past

RKLB shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -2.78%.
The Revenue has grown by 53.92% in the past year. This is a very strong growth!
The Revenue has been growing by 90.82% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-2.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25%
Revenue 1Y (TTM)53.92%
Revenue growth 3Y90.82%
Revenue growth 5YN/A
Sales Q2Q%54.9%

3.2 Future

RKLB is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 28.98% yearly.
The Revenue is expected to grow by 45.04% on average over the next years. This is a very strong growth
EPS Next Y-2.45%
EPS Next 2Y7.45%
EPS Next 3Y22.63%
EPS Next 5Y28.98%
Revenue Next Year75.08%
Revenue Next 2Y56.8%
Revenue Next 3Y54.4%
Revenue Next 5Y45.04%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RKLB. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RKLB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as RKLB's earnings are expected to grow with 22.63% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y7.45%
EPS Next 3Y22.63%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RKLB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ROCKET LAB USA INC

NASDAQ:RKLB (12/20/2024, 8:00:01 PM)

After market: 25.2 +0.33 (+1.33%)

24.87

+1.65 (+7.11%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryAerospace & Defense
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)N/A N/A
Inst Owners52.85%
Inst Owner Change-5.08%
Ins Owners10.95%
Ins Owner Change28.49%
Market Cap12.43B
Analysts79
Price Target22.58 (-9.21%)
Short Float %11.12%
Short Ratio2.29
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)17.53%
Min EPS beat(2)12.21%
Max EPS beat(2)22.86%
EPS beat(4)4
Avg EPS beat(4)13.03%
Min EPS beat(4)0.3%
Max EPS beat(4)22.86%
EPS beat(8)5
Avg EPS beat(8)5.69%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-0.38%
Min Revenue beat(2)-1.23%
Max Revenue beat(2)0.46%
Revenue beat(4)1
Avg Revenue beat(4)-2.88%
Min Revenue beat(4)-6.48%
Max Revenue beat(4)0.46%
Revenue beat(8)3
Avg Revenue beat(8)-1.25%
Revenue beat(12)6
Avg Revenue beat(12)1.01%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)10.93%
PT rev (3m)196.05%
EPS NQ rev (1m)0%
EPS NQ rev (3m)4.69%
EPS NY rev (1m)2.14%
EPS NY rev (3m)2.14%
Revenue NQ rev (1m)-0.26%
Revenue NQ rev (3m)10.62%
Revenue NY rev (1m)2.54%
Revenue NY rev (3m)2.47%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 34.16
P/FCF N/A
P/OCF N/A
P/B 29.6
P/tB 43.27
EV/EBITDA N/A
EPS(TTM)-0.37
EYN/A
EPS(NY)-0.32
Fwd EYN/A
FCF(TTM)-0.29
FCFYN/A
OCF(TTM)-0.18
OCFYN/A
SpS0.73
BVpS0.84
TBVpS0.57
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -16.33%
ROE -44.86%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 26.06%
FCFM N/A
ROA(3y)-15.03%
ROA(5y)-17.99%
ROE(3y)-23.3%
ROE(5y)-28.61%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.32
Health
Industry RankSector Rank
Debt/Equity 0.97
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 171.22%
Cap/Sales 15.38%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.58
Quick Ratio 2.16
Altman-Z 9.47
F-Score6
WACC9.72%
ROIC/WACCN/A
Cap/Depr(3y)187.47%
Cap/Depr(5y)250.93%
Cap/Sales(3y)27.93%
Cap/Sales(5y)39.56%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-2.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25%
EPS Next Y-2.45%
EPS Next 2Y7.45%
EPS Next 3Y22.63%
EPS Next 5Y28.98%
Revenue 1Y (TTM)53.92%
Revenue growth 3Y90.82%
Revenue growth 5YN/A
Sales Q2Q%54.9%
Revenue Next Year75.08%
Revenue Next 2Y56.8%
Revenue Next 3Y54.4%
Revenue Next 5Y45.04%
EBIT growth 1Y-11.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year38.92%
EBIT Next 3Y34.25%
EBIT Next 5Y37.04%
FCF growth 1Y4.3%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y18.98%
OCF growth 3YN/A
OCF growth 5YN/A